Abstract
Tuberculosis is one of the most common infections in Zambian adults and children infected with HIV. In Africa, cutaneous hypersensitivity reactions attributed to thiacetazone during treatment of tuberculosis in adults infected with HIV-I have been well documented. This study monitored adverse drug reactions during treatment for tuberculosis over an 18 month period (1 April 1990 to 31 October 1991) in 237 children with a clinical diagnosis of tuberculosis (125 boys and 112 girls; 88/237 (37%) infected with HIV-I) and 242 control children (149 boys and 93 girls; 26/242 (11%) infected with HIV-I). Twenty two (9%) of the 237 children with tuberculosis developed hypersensitivity skin reactions during the course of treatment. Adverse skin reactions were seen more often in children infected with HIV than in those who were not (odds ratio 11.65, 95% confidence interval 3.07 to 34.88). These represented 19 (21%) of 88 children infected with HIV and three (2%) of 149 children not infected with HIV. These skin reactions occurred after a period of treatment ranging between two and four weeks among 14 children receiving the HST (isoniazid, streptomycin, thiacetazone) regimen and eight children receiving the HSTR (isoniazid, streptomycin, thiacetazone, rifampicin) regimen. Twelve (55%) of the 22 children who reacted adversely to treatment developed the Stevens-Johnson syndrome. All 12 of these children with the Stevens-Johnson syndrome were infected with HIV. The mortality among these children who developed the Stevens-Johnson syndrome was 91% (11 of 12 died within three days of the onset of the reaction). No further reactions were observed in the 11 children who recovered from the cutaneous hypersensitivity reactions after thiacetazone was discontinued over a period of six months of further treatment of tuberculosis. The results of this study were in part responsible for the recommendations put forward by the World Health Organization to avoid the use of thiacetazone in the treatment of tuberculosis in children infected with HIV.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chen W., Samarasinghe P. L. Allergy, oral sex, and HIV. Lancet. 1992 Mar 7;339(8793):627–628. doi: 10.1016/0140-6736(92)90923-q. [DOI] [PubMed] [Google Scholar]
- Colebunders R. L., Ryder R. W., Nzilambi N., Dikilu K., Willame J. C., Kaboto M., Bagala N., Jeugmans J., Muepu K., Francis H. L. HIV infection in patients with tuberculosis in Kinshasa, Zaire. Am Rev Respir Dis. 1989 May;139(5):1082–1085. doi: 10.1164/ajrccm/139.5.1082. [DOI] [PubMed] [Google Scholar]
- De Cock K. M., Gnaore E., Adjorlolo G., Braun M. M., Lafontaine M. F., Yesso G., Bretton G., Coulibaly I. M., Gershy-Damet G. M., Bretton R. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. BMJ. 1991 Mar 2;302(6775):496–499. doi: 10.1136/bmj.302.6775.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Elliott A. M., Luo N., Tembo G., Halwiindi B., Steenbergen G., Machiels L., Pobee J., Nunn P., Hayes R. J., McAdam K. P. Impact of HIV on tuberculosis in Zambia: a cross sectional study. BMJ. 1990 Sep 1;301(6749):412–415. doi: 10.1136/bmj.301.6749.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gilks C. F., Brindle R. J., Otieno L. S., Bhatt S. M., Newnham R. S., Simani P. M., Lule G. N., Okelo G. B., Watkins W. M., Waiyaki P. G. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS. 1990 Oct;4(10):981–985. doi: 10.1097/00002030-199010000-00006. [DOI] [PubMed] [Google Scholar]
- Girling D. J. Adverse effects of antituberculosis drugs. Drugs. 1982 Jan-Feb;23(1-2):56–74. doi: 10.2165/00003495-198223010-00003. [DOI] [PubMed] [Google Scholar]
- Harries A. D. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet. 1990 Feb 17;335(8686):387–390. doi: 10.1016/0140-6736(90)90216-r. [DOI] [PubMed] [Google Scholar]
- Miller A. B., Fox W., Tall R. An international co-operative investigation into thiacetazone (thioacetazone) side-effects. Tubercle. 1966 Mar;47(1):33–74. doi: 10.1016/s0041-3879(66)80051-x. [DOI] [PubMed] [Google Scholar]
- Pearson C. A. Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria. J Trop Med Hyg. 1978 Dec;81(12):238–242. [PubMed] [Google Scholar]
- Raviglione M. C., Narain J. P., Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull World Health Organ. 1992;70(4):515–526. [PMC free article] [PubMed] [Google Scholar]
- Wirima J. J., Harries A. D. Stevens-Johnson syndrome during anti-tuberculosis chemotherapy in HIV-seropositive patients: report on six cases. East Afr Med J. 1991 Jan;68(1):64–66. [PubMed] [Google Scholar]